Under 5 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 311 6.6 5 to 9 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 416 8.8 10 to 14 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 487 10.3 15 to 19 years . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 394 8.4 20 to 24 years . . . . . . . . . . . . . . . . . . . . ...

s screened N = 130 Full-text articles assessed for eligibility N = 23 Studies included in systematic review N = 11 Records excluded N = 107 Full-text articles excluded N = 12 Active surveillance: N = 1 No MRI/US fusion platform used: N = 2 Retrospective: N = 6 Other outcome measure: N = 2 No full text available: N = 1 Fig. 1 Study selection flowchart. 394 © 2015 The Authors BJU International © ...

Meningioma is the most frequent tumor of neuroectodermal origin in humans. It is usually benign. Only a minority of cases shows progression to an anaplastic tumor (WHO grade II and III). Meningioma is generally a sporadic tumor. Multiple and familial cases are rare and mostly associated with (hereditary) neurofibromatosis 2 (NF2). Meningiomas show an unexpectedly high recurrence rate. Also, com...

1. Epi4K Consortium; Epilepsy Phenome/Genome Project; Allen AS et al. De novo mutations in epileptic encephalopathies. Nature 2013: 501 (7466): 217–221. 2. OrhanG, BockM, Schepers D et al. Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy. AnnNeurol 2014: 75 (3): 382–394. 3. Pena SD, Coimbra RL. Ataxia and myoclonic epilepsy due to a heterozygous new muta...

Aaron Sloman How to derive "better" from "is", in American Philosophical Quarterly, Vol 6, Number 1, Jan 1969, pp 43--52. ____________________________________________________________________________ This document is: http://www.cs.bham.ac.uk/research/projects/cogaff/sloman-better.html also available as http://www.cs.bham.ac.uk/research/projects/cogaff/sloman-better.pdf _________________________...